Carboplatin in malignant mesothelioma : a phase II study of the cancer and leukemia group B
Carboplatin (400 mg/m2) was given at 28-day intervals to 41 patients with malignant mesothelioma. In all, 40 patients were eligible and evaluable for response. Partial responses were seen in 2 cases (5%); regression of evaluable disease, in 1 patient (2%); and stable disease, in 19 subjects (48%). A...
Gespeichert in:
| Veröffentlicht in: | Cancer chemotherapy and pharmacology 1990-01, Vol.27 (3), p.239-242 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 242 |
|---|---|
| container_issue | 3 |
| container_start_page | 239 |
| container_title | Cancer chemotherapy and pharmacology |
| container_volume | 27 |
| creator | VOGELZANG, N. J GOUTSOU, M CORSON, J. M SUZUKI, Y GRAZIANO, S AISNER, J COOPER, R COUGHLIN, K. M GREEN, M. R |
| description | Carboplatin (400 mg/m2) was given at 28-day intervals to 41 patients with malignant mesothelioma. In all, 40 patients were eligible and evaluable for response. Partial responses were seen in 2 cases (5%); regression of evaluable disease, in 1 patient (2%); and stable disease, in 19 subjects (48%). A median of two doses of carboplatin per patient resulted in mild toxicity. Leukopenia (less than or equal to 2,000 cells/microliters) and thrombocytopenia (less than 100,000 cells/microliters) were seen in only 6% and 20% of the patients, respectively. Median survival from study entry was estimated at 7.1 months, with a 1-year survival of 25% +/- 7%. Carboplatin given at a dose of 400 mg/m2 at 28-day intervals shows minor activity against malignant mesothelioma. |
| doi_str_mv | 10.1007/BF00685720 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF00685720</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2265461</sourcerecordid><originalsourceid>FETCH-LOGICAL-c312t-d366eb914ce240679e42ba23745527f5e3fd69b46215c22abf4c0a4fff73b0723</originalsourceid><addsrcrecordid>eNpFkEtLw0AUhQdRaq1u3AuzcSNE77wbd7ZYLRTc6MpFuJnMtNG8mEkW_fdGWhQunMX3ceAeQq4Z3DMA87BYAei5MhxOyJRJwROYS3FKpiCkTJQBeU4uYvwCAMmEmJAJ51pJzabkc4khb7sK-7Kh49VYldsGm57WLrb9zlVlWyN9pEi7HUZH12sa-6HY09bTEVOLjXWBYlPQyg3fri6RbkM7dHRxSc48VtFdHXNGPlbP78vXZPP2sl4-bRIrGO-TQmjt8pRJ67gEbVIneY5cGKkUN1454Qud5lJzpiznmHtpAaX33ogcDBczcnfotaGNMTifdaGsMewzBtnvQNn_QKN8c5C7Ia9d8aceFxn57ZFjtFj5MP5Xxv_GVGk5Z1r8ALQ7a80</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Carboplatin in malignant mesothelioma : a phase II study of the cancer and leukemia group B</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>VOGELZANG, N. J ; GOUTSOU, M ; CORSON, J. M ; SUZUKI, Y ; GRAZIANO, S ; AISNER, J ; COOPER, R ; COUGHLIN, K. M ; GREEN, M. R</creator><creatorcontrib>VOGELZANG, N. J ; GOUTSOU, M ; CORSON, J. M ; SUZUKI, Y ; GRAZIANO, S ; AISNER, J ; COOPER, R ; COUGHLIN, K. M ; GREEN, M. R</creatorcontrib><description>Carboplatin (400 mg/m2) was given at 28-day intervals to 41 patients with malignant mesothelioma. In all, 40 patients were eligible and evaluable for response. Partial responses were seen in 2 cases (5%); regression of evaluable disease, in 1 patient (2%); and stable disease, in 19 subjects (48%). A median of two doses of carboplatin per patient resulted in mild toxicity. Leukopenia (less than or equal to 2,000 cells/microliters) and thrombocytopenia (less than 100,000 cells/microliters) were seen in only 6% and 20% of the patients, respectively. Median survival from study entry was estimated at 7.1 months, with a 1-year survival of 25% +/- 7%. Carboplatin given at a dose of 400 mg/m2 at 28-day intervals shows minor activity against malignant mesothelioma.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/BF00685720</identifier><identifier>PMID: 2265461</identifier><identifier>CODEN: CCPHDZ</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Adult ; Aged ; Antineoplastic agents ; Biological and medical sciences ; Carboplatin - adverse effects ; Carboplatin - therapeutic use ; Chemotherapy ; Drug Evaluation ; Female ; Humans ; Male ; Medical sciences ; Mesothelioma - drug therapy ; Mesothelioma - mortality ; Middle Aged ; Pharmacology. Drug treatments ; Survival Rate</subject><ispartof>Cancer chemotherapy and pharmacology, 1990-01, Vol.27 (3), p.239-242</ispartof><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c312t-d366eb914ce240679e42ba23745527f5e3fd69b46215c22abf4c0a4fff73b0723</citedby><cites>FETCH-LOGICAL-c312t-d366eb914ce240679e42ba23745527f5e3fd69b46215c22abf4c0a4fff73b0723</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19564816$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2265461$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>VOGELZANG, N. J</creatorcontrib><creatorcontrib>GOUTSOU, M</creatorcontrib><creatorcontrib>CORSON, J. M</creatorcontrib><creatorcontrib>SUZUKI, Y</creatorcontrib><creatorcontrib>GRAZIANO, S</creatorcontrib><creatorcontrib>AISNER, J</creatorcontrib><creatorcontrib>COOPER, R</creatorcontrib><creatorcontrib>COUGHLIN, K. M</creatorcontrib><creatorcontrib>GREEN, M. R</creatorcontrib><title>Carboplatin in malignant mesothelioma : a phase II study of the cancer and leukemia group B</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><description>Carboplatin (400 mg/m2) was given at 28-day intervals to 41 patients with malignant mesothelioma. In all, 40 patients were eligible and evaluable for response. Partial responses were seen in 2 cases (5%); regression of evaluable disease, in 1 patient (2%); and stable disease, in 19 subjects (48%). A median of two doses of carboplatin per patient resulted in mild toxicity. Leukopenia (less than or equal to 2,000 cells/microliters) and thrombocytopenia (less than 100,000 cells/microliters) were seen in only 6% and 20% of the patients, respectively. Median survival from study entry was estimated at 7.1 months, with a 1-year survival of 25% +/- 7%. Carboplatin given at a dose of 400 mg/m2 at 28-day intervals shows minor activity against malignant mesothelioma.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Carboplatin - adverse effects</subject><subject>Carboplatin - therapeutic use</subject><subject>Chemotherapy</subject><subject>Drug Evaluation</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mesothelioma - drug therapy</subject><subject>Mesothelioma - mortality</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Survival Rate</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkEtLw0AUhQdRaq1u3AuzcSNE77wbd7ZYLRTc6MpFuJnMtNG8mEkW_fdGWhQunMX3ceAeQq4Z3DMA87BYAei5MhxOyJRJwROYS3FKpiCkTJQBeU4uYvwCAMmEmJAJ51pJzabkc4khb7sK-7Kh49VYldsGm57WLrb9zlVlWyN9pEi7HUZH12sa-6HY09bTEVOLjXWBYlPQyg3fri6RbkM7dHRxSc48VtFdHXNGPlbP78vXZPP2sl4-bRIrGO-TQmjt8pRJ67gEbVIneY5cGKkUN1454Qud5lJzpiznmHtpAaX33ogcDBczcnfotaGNMTifdaGsMewzBtnvQNn_QKN8c5C7Ia9d8aceFxn57ZFjtFj5MP5Xxv_GVGk5Z1r8ALQ7a80</recordid><startdate>19900101</startdate><enddate>19900101</enddate><creator>VOGELZANG, N. J</creator><creator>GOUTSOU, M</creator><creator>CORSON, J. M</creator><creator>SUZUKI, Y</creator><creator>GRAZIANO, S</creator><creator>AISNER, J</creator><creator>COOPER, R</creator><creator>COUGHLIN, K. M</creator><creator>GREEN, M. R</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19900101</creationdate><title>Carboplatin in malignant mesothelioma : a phase II study of the cancer and leukemia group B</title><author>VOGELZANG, N. J ; GOUTSOU, M ; CORSON, J. M ; SUZUKI, Y ; GRAZIANO, S ; AISNER, J ; COOPER, R ; COUGHLIN, K. M ; GREEN, M. R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c312t-d366eb914ce240679e42ba23745527f5e3fd69b46215c22abf4c0a4fff73b0723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Carboplatin - adverse effects</topic><topic>Carboplatin - therapeutic use</topic><topic>Chemotherapy</topic><topic>Drug Evaluation</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mesothelioma - drug therapy</topic><topic>Mesothelioma - mortality</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>VOGELZANG, N. J</creatorcontrib><creatorcontrib>GOUTSOU, M</creatorcontrib><creatorcontrib>CORSON, J. M</creatorcontrib><creatorcontrib>SUZUKI, Y</creatorcontrib><creatorcontrib>GRAZIANO, S</creatorcontrib><creatorcontrib>AISNER, J</creatorcontrib><creatorcontrib>COOPER, R</creatorcontrib><creatorcontrib>COUGHLIN, K. M</creatorcontrib><creatorcontrib>GREEN, M. R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>VOGELZANG, N. J</au><au>GOUTSOU, M</au><au>CORSON, J. M</au><au>SUZUKI, Y</au><au>GRAZIANO, S</au><au>AISNER, J</au><au>COOPER, R</au><au>COUGHLIN, K. M</au><au>GREEN, M. R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Carboplatin in malignant mesothelioma : a phase II study of the cancer and leukemia group B</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>1990-01-01</date><risdate>1990</risdate><volume>27</volume><issue>3</issue><spage>239</spage><epage>242</epage><pages>239-242</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><coden>CCPHDZ</coden><abstract>Carboplatin (400 mg/m2) was given at 28-day intervals to 41 patients with malignant mesothelioma. In all, 40 patients were eligible and evaluable for response. Partial responses were seen in 2 cases (5%); regression of evaluable disease, in 1 patient (2%); and stable disease, in 19 subjects (48%). A median of two doses of carboplatin per patient resulted in mild toxicity. Leukopenia (less than or equal to 2,000 cells/microliters) and thrombocytopenia (less than 100,000 cells/microliters) were seen in only 6% and 20% of the patients, respectively. Median survival from study entry was estimated at 7.1 months, with a 1-year survival of 25% +/- 7%. Carboplatin given at a dose of 400 mg/m2 at 28-day intervals shows minor activity against malignant mesothelioma.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>2265461</pmid><doi>10.1007/BF00685720</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0344-5704 |
| ispartof | Cancer chemotherapy and pharmacology, 1990-01, Vol.27 (3), p.239-242 |
| issn | 0344-5704 1432-0843 |
| language | eng |
| recordid | cdi_crossref_primary_10_1007_BF00685720 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Aged Antineoplastic agents Biological and medical sciences Carboplatin - adverse effects Carboplatin - therapeutic use Chemotherapy Drug Evaluation Female Humans Male Medical sciences Mesothelioma - drug therapy Mesothelioma - mortality Middle Aged Pharmacology. Drug treatments Survival Rate |
| title | Carboplatin in malignant mesothelioma : a phase II study of the cancer and leukemia group B |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T17%3A46%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Carboplatin%20in%20malignant%20mesothelioma%20:%20a%20phase%20II%20study%20of%20the%20cancer%20and%20leukemia%20group%20B&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=VOGELZANG,%20N.%20J&rft.date=1990-01-01&rft.volume=27&rft.issue=3&rft.spage=239&rft.epage=242&rft.pages=239-242&rft.issn=0344-5704&rft.eissn=1432-0843&rft.coden=CCPHDZ&rft_id=info:doi/10.1007/BF00685720&rft_dat=%3Cpubmed_cross%3E2265461%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/2265461&rfr_iscdi=true |